BridgeBio Historical Income Statement
| BBIO Stock | USD 27.09 0.40 1.46% |
Historical analysis of BridgeBio Pharma income statement accounts such as Depreciation And Amortization of 6.8 M, Interest Expense of 85.4 M or Selling General Administrative of 123 M can show how well BridgeBio Pharma performed in making a profits. Evaluating BridgeBio Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BridgeBio Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BridgeBio Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BridgeBio Pharma is a good buy for the upcoming year.
BridgeBio |
About BridgeBio Income Statement Analysis
BridgeBio Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BridgeBio Pharma shareholders. The income statement also shows BridgeBio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BridgeBio Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BridgeBio Pharma. It is also known as BridgeBio Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from BridgeBio Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.At this time, BridgeBio Pharma's Interest Income is very stable compared to the past year. As of the 30th of November 2024, Depreciation And Amortization is likely to grow to about 6.8 M, though Net Interest Income is likely to grow to (60.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 5.8M | 6.8M | 6.5M | 4.2M | Total Operating Expenses | 646.3M | 546.1M | 614.2M | 443.3M |
BridgeBio Pharma income statement Correlations
Click cells to compare fundamentals
BridgeBio Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BridgeBio Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 150K | (32.6M) | (45.6M) | (72.9M) | (63.3M) | (60.1M) | |
| Interest Income | 8.9M | 4.0M | 1.1M | 7.5M | 18.0M | 18.9M | |
| Depreciation And Amortization | (13.2M) | 3.1M | 5.8M | 6.8M | 6.5M | 6.8M | |
| Interest Expense | 8.8M | 36.7M | 46.8M | 80.4M | 81.3M | 85.4M | |
| Selling General Administrative | 94.4M | 145.7M | 192.2M | 143.2M | 150.6M | 123.0M | |
| Total Revenue | 40.6M | 8.2M | 69.7M | 77.6M | 9.3M | 8.8M | |
| Other Operating Expenses | 306.8M | 482.7M | 646.3M | 546.1M | 616.7M | 444.1M | |
| Operating Income | (266.2M) | (474.5M) | (579.7M) | (471.9M) | (607.4M) | (577.0M) | |
| Net Income From Continuing Ops | (288.6M) | (505.5M) | (586.5M) | (484.7M) | (653.3M) | (620.6M) | |
| Ebit | (266.2M) | (468.8M) | (539.7M) | (404.2M) | (572.0M) | (543.4M) | |
| Research Development | 209.9M | 337.0M | 454.1M | 402.9M | 455.7M | 319.1M | |
| Ebitda | (279.4M) | (465.7M) | (533.8M) | (397.4M) | (565.5M) | (537.2M) | |
| Total Operating Expenses | 304.3M | 482.7M | 646.3M | 546.1M | 614.2M | 443.3M | |
| Income Before Tax | (288.6M) | (505.5M) | (586.5M) | (484.7M) | (653.3M) | (620.6M) | |
| Total Other Income Expense Net | (22.3M) | (31.0M) | (9.8M) | 27.6M | (45.9M) | (43.6M) | |
| Net Income Applicable To Common Shares | (260.6M) | (448.7M) | (562.5M) | (481.2M) | (433.1M) | (454.7M) | |
| Net Income | (260.4M) | (483.9M) | (639.3M) | (494.0M) | (643.2M) | (611.0M) | |
| Income Tax Expense | (28.1M) | (21.6M) | 52.8M | 9.3M | 71.5M | 75.1M | |
| Minority Interest | 67.5M | (56.8M) | (23.9M) | 3.5M | 10.0M | 7.6M |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.56 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.55 | BHC | Bausch Health Companies | PairCorr |
| 0.48 | GANX | Gain Therapeutics | PairCorr |
| 0.44 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.